Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3WQNY)

• Drug Name: 4-Hydroxybenzoicacid Drug Info
• Cross-matching ID:
  PubChem CID: 135
  ChEBI ID: CHEMBL441343
  CAS Number: CAS 99-96-7
  TTD Drug ID: DM3WQNY

Molecule-Related Drug Atlas

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[4]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[5]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[6]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[7]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[8]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[9]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[10]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[11]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[12]
Budipine	DMODHQI	Migraine	8A80	Approved	[13]

Drug(s) Affected By Aldo-keto reductase family 1 member C4 (AKR1C4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[2]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[14]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[15]
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[16]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[16]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[17]
Nitrazepam	DMEGIQ6	Epilepsy	8A60-8A68	Approved	[14]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[14]
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[18]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[19]

Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[20]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[21]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[14]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[22]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[22]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[21]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[21]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[23]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]

Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[21]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[14]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[26]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[27]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[21]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[28]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[29]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[21]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[30]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[31]

Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[32]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[21]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[14]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[21]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[21]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[34]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[35]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[33]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[21]

Drug(s) Affected By Biotin--protein ligase (HLCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[36]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[37]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[3]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[38]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[39]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[40]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[41]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[42]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[36]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[2]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[2]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[2]
Aldo-keto reductase family 1 member C4 (AKR1C4)	OTW2MMOF	AK1C4_HUMAN	Gene/Protein Processing	[2]
Biotin--protein ligase (HLCS)	OTPDUX30	BPL1_HUMAN	Gene/Protein Processing	[3]

References

• [1] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [2] Initro CAPE inhibitory activity towards human AKR1C3 and the molecular basis. Chem Biol Interact. 2016 Jun 25;253:60-5.
• [3] Resveratrol compounds inhibit human holocarboxylase synthetase and cause a lean phenotype in Drosophila melanogaster. J Nutr Biochem. 2015 Nov;26(11):1379-84. doi: 10.1016/j.jnutbio.2015.07.004. Epub 2015 Jul 26.
• [4] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [5] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [6] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [8] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [9] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [10] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [11] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [13] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
• [14] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [15] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [16] Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact. 2003 Feb 1;143-144:503-13.
• [17] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [18] Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
• [19] Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
• [20] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [21] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [22] Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
• [23] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [24] AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
• [25] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [26] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [27] A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
• [28] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [29] Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
• [30] Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
• [31] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [32] Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
• [33] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [34] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [35] Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
• [36] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [37] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [38] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [39] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [40] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [41] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [42] Chromium(VI) causes down regulation of biotinidase in human bronchial epithelial cells by modifications of histone acetylation. Toxicol Lett. 2011 Aug 28;205(2):140-5. doi: 10.1016/j.toxlet.2011.05.1032. Epub 2011 May 27.